**Supplementary Table 1:** **Anti-Drug Antibody Analysis (Anti-Drug Antibody Analysis Set)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 |
| **Variable, n (%)** | **0.3 mg/kg Q2W** | **1 mg/kg Q2W** | **3 mg/kg Q2W** | **10 mg/kg Q2W** | **3 mg/kg Q3W** | **200 mg Q3W** | **Total** |
| **(n=1)** | **(n=3)** | **(n=9)** | **(n=3)** |  **(n=9)** | **(n=10)** | **(N=35)** |
| **Baseline** |
|  Positive | 0 | 0 | 0 | 0 | 2 (22.2) | 1 (10.0) | 3 (8.6) |
|  Negative | 1 (100) | 3 (100) | 9 (100) | 3 (100) | 7 (77.8) | 9 (90.0) | 32 (91.4) |
| **At least one positive result after dosing** | 1 (100) | 2 (66.7) | 3 (33.3) | 1 (33.3) | 4 (44.4) | 4 (40.0) | 15 (42.9) |

ADA, Anti-drug antibody;

**Supplementary Table 2:** **Neutralizing Antibody Analysis (Anti-Drug Antibody Analysis Set)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 |
| **Variable, n (%)** | **0.3 mg/kg Q2W** | **1 mg/kg Q2W** | **3 mg/kg Q2W** | **10 mg/kg Q2W** | **3 mg/kg Q3W** | **200 mg Q3W** | **Total** |
| **(n=1)** | **(n=3)** | **(n=9)** | **(n=3)** |  **(n=9)** | **(n=10)** | **(N=35)** |
| **Baseline** |
|  Positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|  Negative | 1 (100) | 3 (100) | 9 (100) | 3 (100) | 9 (100) | 10 (100) | 35 (100) |
| **At least one positive result after dosing** | 0 | 0 | 1 (11.1) | 0 | 1 (11.1) | 0 | 2 (5.7) |

Nab, Neutralizing antibody; ADA, Anti-drug antibody;

**Supplementary Table 3 Pharmacokinetics of QL1604 at Steady State (Pharmacokinetics Population)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 　 | 　 |  | 　 |  |  | 　 |
| **Variable** | **1 mg/kg Q2W** | **3 mg/kg Q2W** | **10 mg/kg Q2W** | **3 mg/kg Q3W** | **200 mg Q3W** |
| **(n=2)** | **(n=3)** | **(n=2)** |  **(n=3)** | **(n=2)** |
| AUC0-t,ss ( h\*μg/mL), geometric mean (CV%) | 7700 (26.2) | 3800 (3158.1) | 50500 (3.9) | 20300 (71.6) | 27000 (12.8) |
| Cssmax (μg/mL), geometric mean (CV%) | 35.4262 (9.1) | 60.9657 (224.9) | 414.1413 (6.7) | 71.7859 (60.3) | 92.6603 (15.8) |
| Tmax,ss (h), median (range) | 2.04 (1.08-3.00) | 7.00 (1.08-7.00) | 1.08 (1.08-1.08) | 1.08 (1.08-7.00) | 12.985 (0.97-25.00) |
| Cssmin (μg/mL), geometric mean (CV%) | 16.1299 (20.5) | 69.4109 (9.9) | 194.1807 (2.0) | 20.6943 (124.3) | 29.2527 (12.0) |
| Css-av (μg/mL), geometric mean (CV%) | 21.6721 (18.0) | 88.6131 (12.7)a | 236.2721 (12.8) | 39.9750 (73.3) | 53.3832 (13.4) |
| Rac, geometric mean (CV%) | 2.799 (57.3) | 2.477 (62.6)a | 1.548 (24.0) | 1.867 (20.9) | 1.669 (12.3) |
| DF (%),geometric mean (CV%) | 88.605 (18.4) | 69.824 (12.0)a | 93.010 (23.9) | 123.590 (30.7) | 118.750 (4.1) |

AUC0-t,ss, area under the curve from zero up to a definite time t at steady sate; Cssmax, maximum concentration at steady state; Tmax,ss, time to maximum concentration at steady state; Cssmin, minimum concentration at steady state; Css-av, average concentration at steady state; CV, coefficient of variation; Rac, drug accumulation ratio; DF, degree of fluctuation.

Note:

1. n=2

**Supplementary Figure 1: Waterfall Plot of the Best Percentage Change from Baseline in Target Lesion (Full Analysis Set)**



BOR, best overall response; PD, progressive disease; SD, stable disease; PR, partial response

Note: Four patients didn’t have a post-baseline tumor assessment. One patient had PD and the target lesion was not measurable for this patient.

**Supplementary Figure 2: Individual Tumor Response and Treatment Duration Swimmer Plot (Full Analysis Set)**



GC/GEJ, gastric cancer/ gastroesophageal junction cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; SCLC, small-cell lung cancer

Efficacy by investigator review per RECIST v1.1. The length of the bar represents the duration of treatment with QL1604.

**Supplementary Figure 3: Spider Plot of the Change from Baseline in Target Lesion Size (Full Analysis Set)**

